Objective: This study examines attitudes of mental health professionals about the use and
usefulness of depot antipsychotic medications and determines similarities and differences in …

Background: Since 2002, a second-generation depot antipsychotic has been available that
potentially combines the advantages of depot administration and the favorable aspects of …

In many countries fewer than 20% of individuals with schizophrenia receive depot
antipsychotic medication. Frequently stated reasons are psychiatrist's, patient's and relative's …

Background. Maintenance antipsychotic medication is the mainstay of relapse prevention in
patients with schizophrenia. Long acting depot antipsychotics were developed to promote …

Background: Antipsychotic medications significantly ameliorate the symptoms of
schizophrenia, but patients are often noncompliant with these medications. Research …

Antipsychotic depots are less frequently prescribed than oral compounds. In an
experimental study involving N= 106 psychiatrists we studied how much more effective with …

Utilization of long‐acting antipsychotic injections (depots) shows wide regional variation. In
many countries, community psychiatric nurses (CPNs) administer depots but their concerns …

BackgroundDepot antipsychotic medication is used widely in the treatment and prophylaxis
of severe mental illness. AimsTo review the literature on patient and nurse satisfaction with …

Some clinicians believe that antipsychotic depot injections are unacceptable to patients.
This cross-sectional study investigated patients' attitudes regarding antipsychotics, and …

In spite of their well known advantages, depot antipsychotics are seldom prescribed in the
treatment of schizophrenia. A frequently stated reason is the patient's objection to depot …